Browse drugs

… S, Wong A, Yong WP, Soo RA, Chee CE, Tan DS. 458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Ca…

…im T-Y, Tai WMD, Kang Y-K, Lau G, et al. Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: resu…

…after surgery, neoadjuvant nivolumab prior to surgery, adjuvant pembrolizumab and atezolizumab after surgery, perioperative durvalumab and pe…

…receiving durvalumab, 25% receiving cemiplimab, 66.7% receiving avelumab, and 60% receiving the ipilimumab and nivolumab. A 61.5% of irA…

…age small cell lung cancer. Oncologist 2021;26:433-8.Imdelltra (tarlatamab). Full Prescribing Information, Amgen Inc, Thousand Oaks, CA, U…

…Ref Funder ID: 10.13039/100004755), which provides avelumab and tuvusertib.Trial Registration NCT05947500References Vendetti FP, Karukonda…

…ssion quartiles in a subgroup of patients with CRC treated with pembrolizumab (n=500). The CXCR4high cohort showed significantly improved sur…

…Background Combination immunotherapies such as atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (D…

…gimens for rNSCLC were durvalumab, nivolumab, pembrolizumab and toripalimab. The estimated hazard ratio of immunotherapy regimens for the a…

…Results In 2023 and 2024 we used seven immunotherapeutic drugs: pembrolizumab (230 patients), durvalumab (45 patients), atezolizumab (45 pati…

… of patients, and 12.5% had CNS metastases. Treatments included pembrolizumab (71.9%), nivolumab (21.9%) and durvalumab (6.3%); 71.9% receive…

…se of a patient with hepatocellular carcinoma on durvalumab and tremelimumab who developed severe ICI pneumonitis and acute hypoxic respirat…